AbbVie faces pressure to diversify its portfolio as Humira, the world’s best-selling drug, faces increased competition from cheaper versions in Europe.
The acquisition of Zeltiq Aesthetics' system for using cooling to eliminate fat cells gives Allergan access to the growing body-contouring market.
